WealthTrust Axiom’s PDL BioPharma, Inc. PDLI Stock Holding History

WealthTrust Axiom’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-34,000	Closed	-$79K	–	243
2018 Q2	$79K	Hold	34,000	–	–	0.03%	217
2018 Q1	$99K	Buy	34,000 +1,000	+3%	+$2.73K	0.04%	214
2017 Q4	$90K	Hold	33,000	–	–	0.03%	214
2017 Q3	$111K	Buy	33,000 +3,000	+10%	+$8.34K	0.04%	205
2017 Q2	$74K	Hold	30,000	–	–	0.03%	214
2017 Q1	$68K	Hold	30,000	–	–	0.02%	222
2016 Q4	$63K	Hold	30,000	–	–	0.02%	221
2016 Q3	$100K	Hold	30,000	–	–	0.04%	207
2016 Q2	$94K	Hold	30,000	–	–	0.04%	212
2016 Q1	$99K	Buy	30,000 +4,000	+15%	+$12.5K	0.04%	206
2015 Q4	$92K	Buy	26,000 +4,000	+18%	+$16.7K	0.04%	209
2015 Q3	$110K	Buy	22,000 +7,000	+47%	+$40.1K	0.05%	202
2015 Q2	$96K	Buy	15,000 +1,000	+7%	+$6.7K	0.04%	211
2015 Q1	$98K	Buy	+14,000	New	+$101K	0.03%	214

Other funds holding PDLI

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

WealthTrust Axiom's PDLI Position: Q3 2018 in Review

WealthTrust Axiom sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 34,000 shares — an estimated $79K sold.

WealthTrust Axiom first reported a position in PDLI in Q1 2015 and held it in 14 quarters. The position peaked at $111K in Q3 2017. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

WealthTrust Axiom reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
WealthTrust Axiom sold 34,000 PDL BioPharma, Inc. shares in Q3 2018, an estimated $79K.
WealthTrust Axiom first reported a position in PDL BioPharma, Inc. in Q1 2015 and held it in 14 quarters.
WealthTrust Axiom's PDL BioPharma, Inc. position peaked at $111K in Q3 2017.
152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on WealthTrust Axiom's 13F filing for Q3 2018, filed 1 Nov 2018.